Blood transfusion many times works in a life-saving way when a patient is facing a critical situation. However, some patients, such as Jehovah's Witnesses, may refuse their administration because it opposes to their religion beliefs. Thus, clinicians are forced to respect patients' preferences and seek other treatments in order to overcome the obstacle of the transfusion. In 1989, recombinant h...

TO THE EDITOR: In their paper, Lundby et al. (3) state that “the ergogenic effect of rHuEpo on V̇O2max can entirely be explained through the enhancement of the O2-carrying capacity of blood.” The main cause is assumed to be the increased hemoglobin concentration, since the blood volume was not raised and isovolemic hemodilution to control [Hb] decreased V̇O2max markedly. After carefully reading t...

Background: Recombinant human erythropoietin (rHuEpo) abuse by athletes threatens the integrity of sport. Due to overlap in physiological response rHuEpo and altitude exposure, it remains difficult differentiate changes hematological variables caused or altitude, therefore, other molecular methods enhance anti-doping should be explored. Objective: To identify transcriptomic prolonged exposure t...

Anemia is a common, but underestimated and undertreated, complication of patients with cancer receiving chemo- or radiotherapy, and negatively affects their quality of life (QoL). Erythropoietic proteins (EPS) offer an effective treatment of cancer anemia and ameliorate QoL, although their use requires the correct targeting of hemoglobin increase to avoid thromboembolic complications. Currently...

BACKGROUND Optimal response to recombinant human erythropoietin (rHuEpo) in haemodialysis (HD) patients requires provision of sufficient available iron. However, a balance between iron requirements and supplements remains a challenge in clinical practice. Reticulocyte parameters, i.e. reticulocyte haemoglobin content (CHr) and reticulocytes in a high-fluorescence intensity region (HFR), have be...